Ace inhibitor

Tthe FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) an oral medication for the...


The FDA ( U.S. Food and Drug Administration ) has approved Sunosi ( Solriamfetol ) to improve wakefulness in adult...


The SGLT2 inhibitor Canagliflozin ( Invokana ) .... as an adjunct to the standard of care in adults with type...


Ivabradine ( Corlanor ) has been approved in heart failure with reduced ejection fraction ( HFrEF ) and elevated heart...


The FDA ( U.S. Food and Drug Administration ) has approved Rybelsus ( Semaglutide ) oral tablets to improve control...


Several clinical trials studying mutIDH inhibitors in glioma and other solid tumors are ongoing or in planning stages and involve...


The CANVAS trial has shown that Canagliflozin ( Invokana ) was superior to placebo at preventing cardiovascular events. The goal of...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Oxbryta ( Voxelotor ) for the...


European Commission ( EC ) has approved Spravato ( Esketamine ) nasal spray, in combination with a selective serotonin reuptake...


Safinamide mesilate, discovered and developed by Newron Pharmaceuticals ( Milan, Italy ), is a selective monoamine oxidase B ( MAO-B...


Paroxetine is one of the selective serotonin reuptake inhibitors ( SSRIs ) used in the treatment of premature ejaculation. However,...


Inhibition of the P2Y12 receptor by an oral P2Y12 inhibitor with loading doses along with cyclooxygenase-1 inhibition by Aspirin Acetylsalicylic...


Epidermal growth factor receptor inhibitors ( EGFRi ), EGFR tyrosine kinase inhibitors ( TKI ) and anti‐EGFR antibodies commonly develop...


Results from a phase 3 study evaluating Tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis ( OA...


The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...



The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with...


Results of a new subgroup analysis from the phase 3 CREDENCE study, showing Canagliflozin ( Invokana ) has significantly reduced...